Biospyder Technologies, Inc. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): This project will develop and characterize the applic
Biospyder Technologies, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $149,871
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- ES13-009
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION (provided by applicant): This project will develop and characterize the application of RASL-Seq, a multiplexed targeted expression profiling technology that uses q sequencing read-out, to analysis of banked tissues. The technology detects hundreds of RNA targets at once in cell lysates, using oligo ligation, amplification, and next-generation sequencing for quantitation. This highly multiplexed assay will allow a simple, fixed tissue assay protocol that can be applied to different rodent tissues, while delivering a simple expression profiling report. The technology will promote toxicology research by enabling direct comparisons between expression profiles derived from compound screening in vitro to those observed in animals dosed with the same compounds. It will do so at a low cost/sample by multiplexing 20 to 100 or more samples/sequencing run, thus reducing the sequencing cost/sample to 6 from 600. We will optimize the lysis buffer/protocol for formalin-fixed paraffin-embedded (FFPE) tiss